Insider Transactions in Q1 2025 at Liquidia Corp (LQDA)
Insider Transaction List (Q1 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 03
2025
|
Jason Adair Chief Business Officer |
SELL
Open market or private sale
|
Direct |
451
-0.25%
|
$6,765
$15.45 P/Share
|
|
Mar 03
2025
|
Michael Kaseta CFO and COO |
SELL
Open market or private sale
|
Direct |
874
-0.22%
|
$13,110
$15.45 P/Share
|
|
Mar 03
2025
|
Scott Moomaw Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
592
-0.27%
|
$8,880
$15.45 P/Share
|
|
Mar 03
2025
|
Russell Schundler General Counsel |
SELL
Open market or private sale
|
Direct |
930
-0.16%
|
$13,950
$15.45 P/Share
|
|
Feb 28
2025
|
Jason Adair Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,562
+0.85%
|
-
|
|
Feb 28
2025
|
Michael Kaseta CFO and COO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,344
+0.57%
|
-
|
|
Feb 28
2025
|
Scott Moomaw Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,875
+0.85%
|
-
|
|
Feb 28
2025
|
Russell Schundler General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
2,344
+0.4%
|
-
|
|
Jan 27
2025
|
Jason Adair Chief Business Officer |
SELL
Open market or private sale
|
Direct |
445
-0.25%
|
$6,230
$14.2 P/Share
|
|
Jan 21
2025
|
Rajeev Saggar Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,445
-0.9%
|
$31,785
$13.0 P/Share
|
|
Jan 14
2025
|
Russell Schundler General Counsel |
SELL
Open market or private sale
|
Direct |
16,393
-2.78%
|
$180,323
$11.78 P/Share
|
|
Jan 14
2025
|
Roger Jeffs Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
22,343
-2.15%
|
$245,773
$11.78 P/Share
|
|
Jan 14
2025
|
Jason Adair Chief Business Officer |
SELL
Open market or private sale
|
Direct |
4,809
-2.6%
|
$52,899
$11.78 P/Share
|
|
Jan 14
2025
|
Michael Kaseta CFO and COO |
SELL
Open market or private sale
|
Direct |
23,370
-5.5%
|
$257,070
$11.78 P/Share
|
|
Jan 14
2025
|
Scott Moomaw Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
8,362
-3.74%
|
$91,982
$11.78 P/Share
|
|
Jan 14
2025
|
Rajeev Saggar Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
6,249
-2.26%
|
$68,739
$11.78 P/Share
|
|
Jan 11
2025
|
Russell Schundler General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
102,543
+14.81%
|
-
|
|
Jan 11
2025
|
Roger Jeffs Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
229,327
+18.05%
|
-
|
|
Jan 11
2025
|
Jason Adair Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,906
+2.07%
|
-
|
|
Jan 11
2025
|
Jason Adair Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
61,895
+25.47%
|
-
|
|
Jan 11
2025
|
Michael Kaseta CFO and COO |
BUY
Grant, award, or other acquisition
|
Direct |
112,797
+20.97%
|
-
|
|
Jan 11
2025
|
Scott Moomaw Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
69,729
+23.75%
|
-
|
|
Jan 11
2025
|
Rajeev Saggar Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
71,780
+20.6%
|
-
|